

3 October 2011

Proposal to amend the access criteria for lignocaine-containing urethral syringes

PHARMAC is seeking feedback on a proposal to add an endorsement restriction to the listings of lignocaine gel 2%, 10 ml urethral syringe (Pfizer) and lignocaine gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe (Pfizer) in Section B of the Pharmaceutical Schedule from 1 December 2011 as follows:

Subsidised only if prescribed for urethral administration and the prescription is endorsed accordingly.

This proposal would ensure that lignocaine-containing urethral syringes are funded only for urethral administration, as originally intended.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **5 pm on Monday, 17 October 2011** to:

Geraldine MacGibbon
Therapeutic Group Manager
PHARMAC

Email: geraldine.macgibbon@pharmac.govt.nz
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.